Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Last trade$293.51
Day change-$5.775 (-1.93%)
Day range$291.12 – $300.86
Volume647,870
Market cap$48.46B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$48.46B
Price / earnings
47.75×
Price / book
6.52×
Price / sales
14.01×
EV / sales
13.49×
EV / EBITDA
43.38×
Profitability
Earnings per share
$6.27
Return on assets
11.2%
Return on equity
13.66%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.46×
Quick ratio
5.46×
Cash ratio
1.24×
Cash flow
Price / cash flow
29.09×
Price / free cash flow
29.39×
Free cash flow
$1.65B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VEEV, quarterly periods
Line item
Q2 FY2027 Jul 31, 2026
Q1 FY2027 Apr 30, 2026
Q4 FY2026 Jan 31, 2026
Q3 FY2026 Oct 31, 2025
Q2 FY2026 Jul 31, 2025
Q1 FY2026 Apr 30, 2025
Q4 FY2025 Jan 31, 2025
Q3 FY2025 Oct 31, 2024
Revenue
$927.96M
$882.95M
$835.95M
$811.24M
$789.08M
$759.04M
$720.89M
$699.21M
Cost of revenue
$232.01M
$220.92M
$213.48M
$199.47M
$195.25M
$173.82M
$180.99M
$174.39M
Gross profit
$695.95M
$662.02M
$622.47M
$611.77M
$593.83M
$585.22M
$539.9M
$524.82M
Selling, general and administrative
$198.02M
$180.59M
$177.81M
$179.04M
$205.24M
$167.45M
$169.95M
$171.05M
Research and development
$222.92M
$208.32M
$198.79M
$191.88M
$192.68M
$184.03M
$181.53M
$172.41M
Total operating expenses
$420.93M
$388.91M
$376.6M
$370.92M
$397.92M
$351.49M
$351.47M
$343.47M
Operating income
$275.02M
$273.11M
$245.88M
$240.85M
$195.91M
$233.73M
$188.42M
$181.35M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$349.53M
$347.53M
$317.54M
$312.79M
$265.36M
$298.82M
$245.13M
$242.29M
Income taxes
$76.1M
$86.59M
$73.33M
$76.58M
$65.06M
$70.63M
$49.51M
$56.48M
Net income
$273.43M
$260.94M
$244.2M
$236.2M
$200.31M
$228.19M
$195.63M
$185.81M
Net income attributable to common shareholders
$273.43M
$260.94M
$244.2M
$236.2M
$200.31M
$228.19M
$195.63M
$185.81M
EBITDA
$285.89M
$284.7M
$254.19M
$250.56M
$206.03M
$243.55M
$198.36M
$191.29M
Basic earnings per share
$1.68
$1.60
$1.49
$1.44
$1.23
$1.40
$1.20
$1.15
Diluted earnings per share
$1.66
$1.57
$1.48
$1.40
$1.19
$1.37
$1.17
$1.13
Recent news
Company coverage with links to the original publishers.
Vivos Therapeutics reported a Q3 loss of $0.07 per share, beating consensus estimates of $0.30 loss by 76.67%. Revenue came in at $6.41 million, surpassing estimates by 17.15%, though down from $6.78 million year-ago. The stock has declined 95.2% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Bullfrog AI Holdings Inc. (BFRG) reported a Q3 loss of $0.11 per share, missing consensus estimates of $0.09 loss by 22.22%. Revenue came in at $0.06 million, missing estimates by 71.1%. The stock has declined 37.4% year-to-date and received a Zacks Rank #3 (Hold) rating, expected to perform in line with the market.
NeuroPace (NPCE) reported a quarterly loss of $0.03 per share, beating consensus estimates of $0.06 loss by 50%, but missed revenue expectations with $23.1 million versus the estimated $26.9 million. The company has underperformed the S&P 500 by 30.2% year-to-date. With mixed estimate revisions, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Veeva Systems, a cloud-based software provider for the life sciences industry, has outperformed the broader market over the past month with a +2.5% return. The company shows strong earnings growth expectations of +13.8% for the current fiscal year and +10.2% for the next year, with a consistent track record of beating consensus estimates. However, the stock is rated Zacks Rank #3 (Hold) and trades at a premium valuation (Grade D) compared to peers, suggesting it may perform in line with the broader market in the near term.
Devia, an agentic AI platform spun out from Visium, officially launched to help biopharma companies, CDMOs, and CROs manage pharmaceutical deviations. The platform automates deviation investigation workflows from initial report through root cause analysis and CAPA, with built-in traceability for regulatory compliance. After a year of pilot testing with quality teams, Devia claims to have halved investigation time while integrating with existing validated systems like TrackWise and Veeva Vault QMS.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.